




GRI G4 CONTENT INDEX. 2016

THIS IS AN INTERACTIVE PDF,
PRESS THE BUTTON TO BEGIN





GRI G4
CONTENT INDEX

In preparing this Sustainability Report, we chose to follow the G4 Sustainability Reporting Guidelines issued by the Global Reporting Initiative (GRI). We disclose at the core application level and also report a number of additional indicators that are relevant to our business and stakeholders.

CONTENTS

03 Standard Disclosures

06 Economic

08 Environment

10 Social

12 Labor

14 Products

16 Abbreviations



STANDARD
DISCLOSURE

GRI SRS

Ref	Description	Notes	Source
Strategy and analysis			
102-14	Statement from the most senior decision-maker of the organization		SR, page 4
Organizational profile			
102-1	Name of the organization		SR, Page 2
102-2	Primary brands, products and services	Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs. Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion also has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. As specialty medications, Actelion products are subject to regulatory reviews by global health authorities. Actelion's products are currently available in over 60 countries around the globe and are not explicitly banned anywhere.	actelion.com:Products
102-3	Location of organization's headquarters		actelion.com: Contact
102-4	Countries of operation		actelion.com: Actelion Worldwide
102-5	Nature of ownership and legal form		actelion.com: Articles of Association
102-6	Markets served		FR page 9
102-7	Scale of the organization		FR page 5, page 81
102-8	Number of employees	The number of contractors at Actelion is not significant.	SR, page 22
102-41	Employees covered by collective bargaining agreements		actelion.com: Working at Actelion
102-09	Organizations' supply chain	Actelion's tier 1 suppliers are the manufacturers of Actelion's products's API (Active Pharmaceutical Ingredients), finished products and packaging. An annual sustainability risk assessment includes 100% of Actelion's tier 1 supplier. Actelion supports the principles of the Pharmaceutical Supply Chain Initiative (PSCI) and supports its principles for Responsible Supply Chain Management for ethics, labor, health and safety, environment, and related management systems. These principles are part of every new or renegotiated contract and suppliers.	SR, page 6 actelion.com: Policy PDF
102-10	Significant changes to the organization's size, structure, ownership or its supply chain	No significant changes in 2016	

102-11	Precautionary approach		AR, Book 2, page 38
102-12	Economic, environmental and social charters, principles or other initiatives	Universal Declaration on Human Rights, Support for the Pharmaceutical Industry Principles for Responsible Supply Chain Management set by the Pharmaceutical Supply Chain Initiative, Member of the Carbon Disclosure Project, AGV (Arbeitgeber Verband Basel)	
102-13	Memberships of associations and national and international advocacy organizations	Pharmaceutical industry associations: Interpharma (CH), EBE (EU), ABPI (UK), Handelskammer beider Basel (CH), HTAPFrance-ASF, other national associations where Actelion is present	
Identified material aspects and boundaries			
102-45	Entities included in the organization's consolidated financial statements	All entities are covered by the financial report are also covered in the Sustainability report. Certain KPI's apply to headquarters only as indicated in the index.	FR, page 81
102-46	Process for defining the reports content and topic boundaries		SR, page 4
102-47	Material topics identified in the process for defining report content		SR, page 5
103-1	Topic boundary within the organization		website
103-1	Topic boundary outside the organization		website
102-48	Restatements of information	Restatements are handled on a case-by -case basis and either explained in text or using references such as footnotes and endnotes	
102-49	Significant changes from previous reporting period in the material topics and topic boundaries	not applicable	
Stakeholder engagement			
102-40	Stakeholder group engaged by the organization		Website stakeholder engagement
102-42	Basis for identification and selection of stakeholders with whom to engage		Website stakeholder engagement
102-43	Approach to stakeholder engagement		Website stakeholder engagement
102-44	Key topics and concerns raised through stakeholder engagement		SR, page 5
Report profile			
102-50	Reporting period	2016	

102-51	Date of most recent previous report	9-Feb-15	
102-52	Reporting cycle	annual	
102-53	Contact point for questions regarding the report or its contents		investor.relations at actelion.com
102-54	Claims of reporting in accordance with the GRI standards	This report contains Standard Disclosures from the GRI Sustainability Reporting Guidelines	
102-55	GRI content index		GRI content index
102-56	External assurance	CO2 assurance	Assurance report
102-56	External assurance policy	External Assurance of CO2 data only - to be developed further	
Governance			
102-18	Governance structure		Website int. org. structure
Ethics and integrity			
102-16	Organization's values, principles, standards and norms of behavior such as codes of conduct and codes of ethics		SR, page 18



ECONOMIC

G4-EC


Ref	Description	Notes	Source
Economic performance			
201-1	Direct economic value generated and distributed		SR, page 7
205-1	Total number and percentage of operations assessed for risks related to corruption and the significant risks identified		SR, page 18
205-2	Communication and training on anti-corruption policies and procedures	All of Actelion's employees are trained on the Corruption and Bribery policy. Externally, Actelion supports the principles of the Pharmaceutical Supply Chain Initiative (PSCI) These principles are part of every new or renegotiated contract. They include the following: "All corruption, extortion and embezzlement are prohibited. Suppliers shall not pay or accept bribes or participate in other illegal inducements in business or government relationships. Suppliers shall conduct their business consistent with fair and vigorous competition and in compliance with all applicable anti-trust laws. Suppliers shall employ fair business practices, including accurate and truthful advertising".	SR, page 18



ENVIRONMENT

G4 EN

Ref	Description	Notes	Source
Water			
303-1	Total water withdrawal	Headquarter data only -Actelion's water supply stems from the Rhine river. The river water is pumped to two local facilities where it is pre-treated in a sand filter. The water is then allowed to percolate through ditches and ponds. While passing through the ground, microorganisms are filtered out and trace substances are dissipated. Then the mixture of groundwater and infiltrated river water is brought back up to the surface. It is then deacidified, charcoal-filtered and UV-treated before distribution.	SR, page 28
Emissions			
305-1	Direct greenhouse gas emissions (Scope 1)	Global data	SR, page 28
305-2	Indirect greenhouse gas emissions (Scope 2)	Global data	SR, page 28
Waste			
G4-EN23	Total weight of waste by type and disposal method	Headquarter data only	SR, page 28
Compliance			
307-1	Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations	During 2016, no significant fines or non-monetary sanctions for non-compliance with environmental laws and regulations were recorded.	



SOCIAL

G4 S0

Ref	Description	Notes	Source
Compliance			
419-1	Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with laws and regulations	During 2016, no significant fines or non-monetary sanctions for non-compliance with laws and regulations	



LABOR

G4 LA

Ref	Description	Notes	Source
Employment			
401-1	Total number and rates of new employees hires and employee turnover by age group, gender and region		SR, page 23
401-2	Benefits provided to full-time employees that are not provided to temporary or part-time employees, by significant locations of operation		SR, page 23
Occupational health and safety			
403-1	Percentage of total workforce represented in formal joint management-worker health and safety committees that help monitor and advise on occupational health and safety program	HQ - all, office only sites have safety coordinators	
403-2	Type of injury and rats of injury, occupational diseases, lost days and absenteeism and total number of work-related fatalities by region and gender	Headquarter data only	SR, page 26
Training and education			
404-2	Programs for skills management and lifelong learning that support the continued employability of employees and assist them in managing career endings		SR, page 23/24
404-3	Percentage of employees receiving regular performance and career development review, by gender and by employee category	100% of our employees participate in mandatory annual – often biannual – performance reviews	SR, page 25
Diversity and equal opportunity			
405-1	Composition of governance bodies and breakdown of employees per employee category according to gender, age group, minority group membership, and other indicators of diversity		SR, page 23



PRODUCTS

G4 PR

Ref	Description	Notes	Source
Customer health and safety			
416-1	Percentage of significant product and service categories for which health and safety impacts are assessed for improvement	All of our products are continuously assessed for health and safety impacts through pre-marketing clinical trial data and post-marketing pharmacovigilance activities.	
Product and service labeling			
417-1	Type of product and service information required by the organization's procedures for product and service information and labeling, and percentage of significant product and service categories subject to such information requirements	Due to the nature of our business, all of Actelion's products have stringent product information and labeling requirements taking into account national medical practices, regulations and the decisions of the competent health authorities. See the following for links to prescribing information for our marketed therapies	Healthcare Professionals
Marketing communication			
417-3	Total number of incidents of non-compliance with regulations and voluntary codes concerning marketing communications, including advertising, promotion, and sponsorship, by type of outcomes		SR, page 19
Customer privacy			
418-1	Total number of substantiated complaints regarding breaches of customer privacy and losses of customer data		SR, page 18
Compliance			
419-1	Monetary value of significant fines for non-compliance with laws and regulations concerning the provision and use of products and services	During 2016, no significant fines or non-monetary sanctions for non-compliance with laws and regulations concerning the provision and use of products and services were recorded.	

ABBREVIATIONS

AR Annual report

CS&GR Corporate Sustainability & Governance Report

EC Economic indicators

EN Environmental indicators

FR Financial report

GRI Global reporting initiative

LA Labor indicators

PR Products

SD Standard disclosures

SO Social indicators

SR Sustainability report



Actelion Ltd
Gewerbstrasse 16
CH-4123 Allschwil
Switzerland

Phone +41 61 565 65 65
Fax +41 61 565 65 00
info@actelion.com
www.actelion.com

All trademarks are legally protected.
Copyright ©2017 Actelion Pharmaceuticals Ltd.

Details of Actelion Worldwide can be found on
www.actelion.com